Detalhe da pesquisa
1.
Does IPSS-R down staging before transplantation improve the prognosis of patients with Myelodysplastic neoplasms?
Blood
; 2024 May 10.
Artigo
Inglês
| MEDLINE | ID: mdl-38728380
2.
Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease.
Br J Haematol
; 153(2): 244-52, 2011 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-21382020
3.
Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT.
Leukemia
; 34(1): 87-99, 2020 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31363160
4.
5.
Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma.
Br J Haematol
; 141(2): 235-43, 2008 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-18318762
6.
Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma.
Haematologica
; 91(6): 862-3, 2006 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-16769594
7.
Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Marrow Transplantation (EBMT).
Bone Marrow Transplant
; 56(3): 529-531, 2021 03.
Artigo
Inglês
| MEDLINE | ID: mdl-32741961
8.
The impact of donor factors on primary non-engraftment in recipients of reduced intensity conditioned transplants from unrelated donors.
Haematologica
; 90(11): 1562-9, 2005 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-16266905
9.
Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia.
Br J Haematol
; 142(2): 318-20, 2008 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-18492100
10.
Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant Alemtuzumab.
Biol Blood Marrow Transplant
; 13(6): 724-33, 2007 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-17531783
11.
Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution.
Blood
; 99(7): 2586-91, 2002 Apr 01.
Artigo
Inglês
| MEDLINE | ID: mdl-11895797
12.
BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients.
Blood
; 103(2): 428-34, 2004 Jan 15.
Artigo
Inglês
| MEDLINE | ID: mdl-12969983
13.
Expert radiological review of skeletal surveys identifies additional abnormalities in 23% of cases: further evidence for the value of myeloma multi-disciplinary teams in the accurate staging and treatment of myeloma patients.
Br J Haematol
; 137(2): 172-3, 2007 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-17391500
14.
CMV infection following nonmyeloablative allogeneic stem cell transplantation using Campath.
Blood
; 100(10): 3843-4, 2002 Nov 15.
Artigo
Inglês
| MEDLINE | ID: mdl-12411329